^
    almost2years
    ICX-101, a novel MYC inhibitor, shows antitumor activity in patient-derived cells of advanced lung cancer with high MYC expression (AACR 2023)
    ICX-101 is a potent MYC inhibitor that shows antitumor activity in lung cancer PDCs. Our results suggest the potential of ICX-101 as a possible therapeutic option in advanced lung cancer with high MYC expressions.
    Clinical • Metastases
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC expression
    |
    ICX-101